Status:
COMPLETED
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer
Lead Sponsor:
Nektar Therapeutics
Conditions:
Tumor
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients with metastatic or locally advanced breast cancer whose disease has failed prior taxane-based treatment in th...
Eligibility Criteria
Inclusion
- Inoperable metastatic or locally advanced breast cancer
- No more than 2 prior chemotherapy regimens given in a metastatic or locally advanced setting and prior treatment in the metastatic setting must have included a taxane
Exclusion
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to Day 1 of Cycle 1
- Patients who have had any major surgery within 4 weeks prior to Day 1 of Cycle or minor surgery within 2 weeks prior to Day 1 of Cycle 1
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00802945
Start Date
October 1 2008
End Date
January 1 2012
Last Update
July 9 2018
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90089-9177
2
Desert Hematology Oncology Medical Group
Rancho Mirage, California, United States, 92270
3
Stockton Hematology/Oncology
Stockton, California, United States, 95204
4
Mayo Clinic Jacksonville
Jacksonville, Florida, United States, 32224